GROWFIN 1MG FILM COATED TABLETS

Nchi: Kuprosi

Lugha: Kigiriki

Chanzo: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Viambatanisho vya kazi:

FINASTERIDE

Inapatikana kutoka:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

ATC kanuni:

D11AX10

INN (Jina la Kimataifa):

FINASTERIDE

Kipimo:

1MG

Dawa fomu:

FILM COATED TABLETS

Tungo:

FINASTERIDE (8000001325) 1MG

Njia ya uendeshaji:

ORAL USE

Dawa ya aina:

Εθνική Διαδικασία

Eneo la matibabu:

FINASTERIDE

Bidhaa muhtasari:

Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 28 TABS IN BLISTER(S) (300026504) 28 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται

Taarifa za kipeperushi

GROWFIN 1 MG FILM-COATED TABLETS.
Finasteride 1 mg film-coated tablets.
This medicine is for use in men only
IN THIS LEAFLET:
1. What Growfin is and what it is used for
2. Before you take Growfin
3. How to take Growfin
4. Possible side effects
5. How to store Growfin
6. Further information
1. What T is and what
Growfin contains a medicine called finasteride. This belongs to a
group of medicines called Type II
‘5-alpha reductase inhibitors’.
Your doctor has prescribed Growfin because you have male pattern hair
loss (also known as
androgenetic alopecia). Growfin increases hair growth on the scalp and
prevents further hair loss in
men. Men with mild to moderate, but not complete hair loss, can
benefit from using Growfin.
HOW DOES THE HAIR ON YOUR HEAD GROW?
On average your hair grows about 1 centimetre (half an inch) each
month. Hair grows from hair
follicles, which are located under your skin.
A single scalp hair grows continuously for 2-4 years (growth phase)
and then stops growing for 2-4
months (rest phase). After this the hair falls out. In its place a new
healthy hair begins to grow, and
the cycle is repeated. The hairs on your scalp are always in different
stages of this cycle so it is
normal to lose scalp hair every day.
WHAT IS MALE PATTERN HAIR LOSS?
Male pattern hair loss is a common condition in which men experience
thinning of the hair on the
scalp, often resulting in a receding hairline and/or balding on the
top of the head. This condition is
thought to be caused by a combination of genetic factors and a
particular hormone, DHT
(dihydrotestosterone).
1
PATIENT INFORMATION LEAFLET
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE:

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you. Do not pass it on to
others. It may harm them,
even if their symptoms are the same as yours.

If any of the side effects get serious, or if you notice any side
effects not listed

Tabia za bidhaa

1.
NAME OF THE MEDICINAL PRODUCT
Growfin 1 mg
Finasteride 1 mg Film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet of 'Growfin' contains 1 mg of Finasteride as
the active ingredient.
Excipient(s) with known effect: 95.55 mg of lactose monohydrate per
film-coated tablet.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Round biconvex, reddish brown, 7 mm, marked “F1” on one side.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
‘Growfin' is indicated for the treatment of men with male pattern
hair loss (androgenetic alopecia) to
increase hair growth and prevent further hair loss.
'Growfin' is NOT indicated for use in women or children and
adolescents.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The recommended dosage is one 1 mg tablet daily. 'Growfin' may be
taken with or without food.
There is no evidence that an increase in dosage will result in
increased efficacy.
Efficacy and duration of treatment should continuously be assessed by
the treating physician.
Generally, three to six months of once daily treatment are required
before evidence of stabilisation of
1
SUMMARY OF PRODUCT CHARACTERISTICS
hair loss can be expected. Continuous use is recommended to sustain
benefit. If treatment is stopped,
the beneficial effects begin to reverse by six months and return to
baseline by 9 to 12 months.
No dosage adjustment is required in patients with renal insufficiency.
No data are available on the concomitant use of finasteride and
topical minoxidil in male pattern hair
loss.
4.3 CONTRAINDICATIONS
Contraindicated in women: see 4.6 'Pregnancy and lactation' and 5.1
'Pharmacodynamic properties’.
Hypersensitivity to finasteride or to any of the excipients.
'Growfin' is not indicated for use in women or children and
adolescents.
'Growfin' should not be taken by men who are taking finasteride 5 mg
or any other 5α-reductase
inhibitor for benign prostatic hyperplasia or any other condition.
4.4 SPECIAL WARNING AND PRECAUTIONS FOR USE
'Grow